INFLAMMATORY BOWEL DISEASE AND ASSOCIATED SKIN MANIFESTATIONS
DOI:
https://doi.org/10.55519/JAMC-03-13956Keywords:
Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis; Skin manifestationsAbstract
Background: Inflammatory bowel disease (IBD) is a group of chronic inflammatory conditions of the gastrointestinal tract. Skin manifestations are frequently found with IBD yet they are not completely comprehended regarding how common they are and whether they reflect the seriousness of disease. Objective was to determine the prevalence, type and treatment of skin recall manifestations among a cohort of patients with CD and ulcerative colitis (UC). Methods: A total of 250 IBD patients (140 CD and 110 UC) were enrolled in the study. Demographics of patients, disease duration, skin morphology were enrolled. We evaluated the frequency of skin manifestations, their association with disease activity, and course in response to therapy. Results: Skin manifestations appeared in 31.2% of patients, and were more prevalent in CD (35%) compared to UC (26%) (p=0.04). The most common skin manifestations were erythema nodosum (11.2%), pyoderma gangrenosum (5.6%), and perianal skin tags (8%). Active disease demonstrated a significant association with skin manifestations (45% active disease vs 18% remission, p<0.001). Patients receiving anti-TNF therapy had fewer new skin manifestations (20%) when compared to patients receiving conventional therapy (36%) (p=0.03), however 5% of patients receiving biologic therapy reported developing paradoxical skin reactions. Management of skin manifestations consisted mainly of systemic corticosteroid therapy, which was effective in 80% of cases, while 10% of patients with more severe perianal disease underwent surgical intervention to treat their skin manifestations. Conclusion: Skin manifestations appear to be common in patients with IBD, and a significant difference was observed between patients with CD and UC. The disease activity showed a strong association with the occurrence of skin manifestations. Anti-TNF therapy is likely to be associated with less frequent new skin manifestation, however it remains substantive that patients with biologic therapy can have paradoxical skin reactions.References
Harris R, Brown A, Lee J. Novel therapeutic approaches to inflammatory bowel disease: An update. J Gastroenterol Hepatol. 2024;39(1):54-65.
Kumar A, Patel S, Wong K. Immunological mechanisms in the skin manifestations of inflammatory bowel disease. Dermatol Res Pract. 2024;2024:108432.
Lichtenstein GR, Feagan BG, Cohen RD. Management of skin manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2024;22(3):439-52.
Papp K, Bissonnette R, Schachter S. Pyoderma gangrenosum and inflammatory bowel disease: Pathogenesis and management. Am J Clin Dermatol. 2024;25(2):135-44.
Zhao S, Lee T, Chang H. Psoriasis and other cutaneous manifestations in inflammatory bowel disease: A comprehensive review. J Dermatol Treat. 2024;35(4):482-90.
Johnson C, Wang S, Gupta A. Management strategies for complex dermatological manifestations of inflammatory bowel disease. J Clin Gastroenterol. 2024;58(2):123-32.
Smith J, Williams R, Zhang X. The role of JAK inhibitors in treating inflammatory bowel disease and associated skin conditions. Ther Clin Risk Manag. 2024;20:98-106.
Thompson D, Brooks L, O'Neil C. The impact of biologic therapies on cutaneous manifestations in inflammatory bowel disease: A systematic review. Gastroenterology. 2024;166(4):835-44.
Wong S, Wong R, Williams C. The epidemiology of extra-intestinal manifestations in inflammatory bowel disease: A review of recent studies. Inflamm Bowel Dis. 2024;30(6):987-1002.
Greenberg M, Nielson M, Stewart D. Systemic and cutaneous inflammation in inflammatory bowel disease: Insights from recent research. J Inflamm Res. 2024;17:89-100.
Alashkar Alhamwe B, Alhamdan F, Lindner N, Wang J, Stein M, Stockinger J, et al. Skin manifestations in inflammatory bowel disease: Frequency, types, and management strategies. J Clin Gastroenterol. 2023;57(4):331-6.
Nakano H, Ohara Y, Fujimoto M, Yamada T, Takahashi H, Sato Y, et al. Cutaneous manifestations in Crohn's disease and ulcerative colitis: A comprehensive review of epidemiology and management. Dig Dis. 2023;41(2):345-57.
Li P, Wang S, Chen Z, Huang J, Xu T, Li Y, et al. Skin complications and disease activity in inflammatory bowel disease: Insights from a Chinese cohort study. BMC Gastroenterol. 2022;22(1):112.
Marzano AV, Trevisan V, Lazzari R, Agostinelli C, Caputo R, Bonamonte D, et al. Pathogenesis and management of erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. Curr Rheumatol Rep. 2023;25(3):147-57.
Kumar V, Chawla SP, Makhija M, Bhalla S, Sharma R, Gupta M, et al. Dermatological manifestations in patients with inflammatory bowel disease. J Assoc Physicians India. 2022;70(1):11-5.
Mahendran R, Ferreira S, Taylor J, Nuno A, Barton S, Walker G, et al. Incidence and management of paradoxical psoriasis induced by anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2022;28(5):769-75.
Bertani E, Grossi U, Tropini G, Prati M, Kattamis N, Buonomo O, et al. Perianal skin tags in Crohn’s disease: Surgical management and outcomes. Colorectal Dis. 2023;25(6):915-22.
Eder P, Stawczyk-Eder K, Czerwińska-Jelonkiewicz K, Szczepańska A, Mazurek S, Lewandowski M, et al. Effectiveness of biologic therapy on skin manifestations in inflammatory bowel disease: Real-world evidence. Ther Adv Gastroenterol. 2023;16:17562848231121429.
Sahu P, Jha V, Jain A, Sharma S, Singh R, Gupta A, et al. Therapeutic implications of skin manifestations in Crohn's disease and ulcerative colitis. Expert Rev Clin Immunol. 2023;19(1):55-64.
Inoue Y, Nomura K, Nakamura H, Takeda S, Suzuki T, Yamaguchi A, et al. Clinical features and treatment outcomes of erythema nodosum in inflammatory bowel disease patients. Intern Med. 2022;61(19):2943-50.
Li T, Wang H, Zhang H, Zhao W, Feng Y, Liu L, et al. Systemic corticosteroids in the management of extraintestinal manifestations of inflammatory bowel disease: A systematic review. World J Clin Cases. 2023;11(3):405-18.
Kochar B, Herfarth HH, Rubin DT, Szigethy E, Long MD, Osterman MT, et al. Skin manifestations in IBD: Epidemiology, pathogenesis, and treatment. Inflamm Bowel Dis. 2023;29(4):562-74.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Usman Ghani, Mahwish Ahmed, Athar NAyeem, Zunaira Qayyum
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
